Xiao Le joins Gland Pharma International subsidiary
Key Highlights
Gland Pharma informs about appointment of chief investment officer.
Gland Pharma appointed Xiao Le as the Chief Investment Officer of its wholly-owned subsidiary, Gland Pharma International, effective November 09, 2026. The company stated that the new executive will manage investment opportunities and enhance merger and acquisition capabilities for the firm across international markets.
Xiao Le will oversee operations for Gland Singapore and report directly to the CEO of the subsidiary. The role involves identifying potential investments and strengthening the company’s M&A presence in the United States of America, China, Singapore, and other regions.
The company confirmed this appointment in a regulatory filing submitted to the . It noted that the move complies with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Further details regarding the appointment were provided in an annexure enclosed with the official company submission.
Based on company and agency reports. For information only; not investment advice.